August 11, 2025

Thermo Fisher Scientific Inc (TMO) Stock Analysis: A Closer Look at Its 19.77% Potential Upside and Strong Buy Ratings

Thermo Fisher Scientific Inc (NYSE: TMO) stands as a titan in the healthcare sector, operating within the diagnostics and research industry. With a robust market capitalization of $173.97 billion, the..

Agilent Technologies, Inc. (A) Stock Analysis: Unlocking a 19.48% Potential Upside in the Diagnostics & Research Sector

Agilent Technologies, Inc. (NYSE: A), a key player in the Healthcare sector, specializes in providing cutting-edge solutions in the diagnostics and research industry. With a market capitalization of $32.56 billion,..

GSK plc (GSK) Stock Analysis: Unlocking a 3.25% Potential Upside Amid Strong Dividend Yields

GSK plc (GSK), a prominent player in the Healthcare sector, stands out in the Drug Manufacturers – General industry with a substantial market cap of $76.23 billion. Based in the..

Merck & Company, Inc. (MRK) Stock Analysis: Strong Dividend Yield and Significant Upside Potential

Merck & Company, Inc. (NYSE: MRK) stands as a formidable player in the healthcare sector, specifically within the drug manufacturing industry. With a commanding market capitalization of $201.55 billion, Merck..

Medtronic plc (MDT) Stock Analysis: Exploring a 4.33% Potential Upside in the Robust Medical Devices Sector

Medtronic plc (NYSE: MDT), a titan in the healthcare sector, stands out as a dominant force in the medical devices industry with a market capitalization of $119 billion. Headquartered in..

Zoetis Inc. (ZTS) Stock Analysis: A 29% Upside Potential with Strong Buy Ratings

Investors seeking potential growth in the healthcare sector may find Zoetis Inc. (NYSE: ZTS) an intriguing opportunity. As a leading player in the specialized drug manufacturing industry, Zoetis stands out..

Alcon Inc. (ALC) Stock Analysis: Exploring a 22.65% Potential Upside for Investors

Alcon Inc. (NYSE: ALC), a global leader in eye care products, has captured the attention of investors with a promising potential upside of 22.65%. Headquartered in Geneva, Switzerland, Alcon operates..

Gilead Sciences, Inc. (GILD): Investor Outlook Amid Strong 2.65% Dividend Yield and Impressive Return on Equity

Gilead Sciences, Inc. (NASDAQ: GILD), a heavyweight in the healthcare sector, continues to attract investor attention with its robust portfolio of pharmaceuticals aimed at addressing critical unmet medical needs globally...

Pfizer, Inc. (PFE) Stock Analysis: Navigating a 17.4% Potential Upside with a Robust 7% Dividend Yield

Pfizer, Inc. (NYSE: PFE), a stalwart in the healthcare sector, has long been a cornerstone of drug manufacturing, recognized globally for its biopharmaceutical innovations. With a market capitalization of $139.75..

Cencora, Inc. (COR) Stock Analysis: Exploring a 16.46% Potential Upside in Healthcare Distribution

Cencora, Inc. (COR), a stalwart in the healthcare sector with a focus on medical distribution, is capturing investor interest with a promising potential upside of 16.46%. As the company continues..

AstraZeneca PLC (AZN) Stock Analysis: Exploring a 17.78% Potential Upside

AstraZeneca PLC (AZN), a leading player in the healthcare sector, continues to capture investor interest with its robust pipeline and strategic collaborations. Headquartered in Cambridge, UK, AstraZeneca specializes in the..

Stryker Corporation (SYK) Stock Analysis: Healthcare Giant with 14.48% Upside Potential

Stryker Corporation (NYSE: SYK) stands as a formidable name in the healthcare sector, specializing in medical devices. With a market capitalization of $144.35 billion, Stryker’s influence and reach are substantial,..

Johnson & Johnson (JNJ) Stock Analysis: Evaluating the Healthcare Giant’s Growth Potential and Market Position

For investors seeking stability in the ever-fluctuating market, Johnson & Johnson (NYSE: JNJ) presents itself as a stalwart in the healthcare sector. With a market capitalization of $417.44 billion, the..

Eli Lilly and Company (LLY) Stock Analysis: A Look at 46.37% Potential Upside and Robust Revenue Growth

Eli Lilly and Company (NYSE: LLY), a prominent figure in the healthcare sector, is drawing significant attention from investors due to its impressive revenue growth and a potential upside of..

Intuitive Surgical, Inc. (ISRG) Stock Analysis: Exploring a 24% Upside Potential Amid Strong Revenue Growth

Intuitive Surgical, Inc. (NASDAQ: ISRG) stands out as a formidable player in the healthcare sector, specifically within the medical instruments and supplies industry. With a market capitalization of $168.51 billion,..

Plus500 reports H1 2025 revenue of $415.1m and record customer deposits

Plus500 has reported first-half 2025 revenue of $415.1m and EBITDA of $185.1m, supported by record customer deposits of $3.1bn, more than double last year...

Oxford Nanopore CEO Gordon Sanghera to step down

Oxford Nanopore has announced that CEO and co-founder Gordon Sanghera will step down by the end of 2026 after more than 20 years leading the company. The Board has begun..

GSK’s Gepotidacin receives US FDA Priority Review for gonorrhoea treatment

GSK has announced that the US FDA has accepted for priority review a supplemental New Drug Application for gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea in patients aged..

Nuformix applies for US Orphan Drug Designation for NXP002 in IPF

Nuformix has submitted an application to the US FDA for Orphan Drug Designation for tranilast, the active ingredient in its NXP002 inhaled therapy for idiopathic pulmonary fibrosis...

Dekel Agri-Vision sees record cashew output, higher palm oil prices

Dekel Agri-Vision has announced a July 2025 update, highlighting record monthly raw cashew nut processing of 533 tonnes at its Tiebissou plant, up 423% from July 2024...
Search

Funds

August 11, 2025

Plus500 reports H1 2025 revenue of $415.1m and record customer deposits

Plus500 has reported first-half 2025 revenue of $415.1m and EBITDA of $185.1m, supported by record customer deposits of $3.1bn, more than double last year...

Oxford Nanopore CEO Gordon Sanghera to step down

Oxford Nanopore has announced that CEO and co-founder Gordon Sanghera will step down by the end of 2026 after more than 20 years leading the company. The Board has begun a formal search for his successor as part of its succession planning, aiming to guide the business through its next phase of growth and commercialisation...

GSK’s Gepotidacin receives US FDA Priority Review for gonorrhoea treatment

GSK has announced that the US FDA has accepted for priority review a supplemental New Drug Application for gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea in patients aged 12 and over...

Nuformix applies for US Orphan Drug Designation for NXP002 in IPF

Nuformix has submitted an application to the US FDA for Orphan Drug Designation for tranilast, the active ingredient in its NXP002 inhaled therapy for idiopathic pulmonary fibrosis...

Dekel Agri-Vision sees record cashew output, higher palm oil prices

Dekel Agri-Vision has announced a July 2025 update, highlighting record monthly raw cashew nut processing of 533 tonnes at its Tiebissou plant, up 423% from July 2024...
Search

Funds

August 11, 2025

FTSE 100

Funds